ストックスクリーナーアプリを入手
0.7163
0.33%
-0.0024
アフターアワーズ：
.69
-0.0263
-3.67%
前日終値:
$0.7187
開ける：
$0.7068
24時間の取引高:
438.13K
Relative Volume:
0.43
時価総額：
$115.86M
収益：
-
当期純損益:
$-274.18M
株価収益率:
-0.2826
EPS:
-2.5346
ネットキャッシュフロー:
$-198.33M
1週間 パフォーマンス:
+5.38%
1か月 パフォーマンス:
-6.61%
6か月 パフォーマンス:
-92.79%
1年 パフォーマンス:
-92.61%
1日の値動き範囲:
$0.6983
$0.7267
1週間の範囲:
$0.6607
$0.7302
52週間の値動き範囲:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
名前
Neumora Therapeutics Inc
セクター
電話
(857) 760-0900
住所
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.7163 | 109.94M | 0 | -274.18M | -198.33M | -2.5346 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-03-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-07 | ダウングレード | Stifel | Buy → Hold |
| 2025-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-10-10 | 開始されました | BofA Securities | Buy |
| 2023-10-10 | 開始されました | Guggenheim | Buy |
| 2023-10-10 | 開始されました | JP Morgan | Overweight |
| 2023-10-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-10 | 開始されました | Stifel | Buy |
| 2023-10-10 | 開始されました | William Blair | Outperform |
すべてを表示
Neumora Therapeutics Inc (NMRA) 最新ニュース
Neumora Therapeutics Holds Annual Stockholders Meeting - TipRanks
BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Deutsche Bank AG Has $775,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm - GlobeNewswire Inc.
26,500 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Bought by Janus Henderson Group PLC - Defense World
Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development - Investing.com India
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Price T Rowe Associates Inc. MD Cuts Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp - Defense World
Orbimed Advisors LLC Has $8.53 Million Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk - Investing.com Australia
The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com India
Neumora Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice - marketscreener.com
What is HC Wainwright’s Forecast for NMRA Q2 Earnings? - Defense World
William Blair Analysts Increase Earnings Estimates for NMRA - Defense World
Neumora Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - The Malaysian Reserve
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating - TipRanks
Neumora Therapeutics Venture Debt Facility - Leerink Partners
Neumora Therapeutics (NMRA) Retains Buy Rating with Stable Price Target | NMRA Stock News - GuruFocus
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements - TipRanks
Neumora Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Neumora Therapeutics Q1 2025 Sees Net Loss, Stock Rises - Investing.com
Neumora Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Transcript : Neumora Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely? - Yahoo Finance
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday - Defense World
Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com
Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World
Should investors be concerned about Neumora Therapeutics Inc (NMRA)? - uspostnews.com
NMRA stock rated an Underperform by BofA Securities - knoxdaily.com
Neumora Therapeutics Inc (NMRA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):